IMNN (Imunon) רווח למניה לשנה מתגלגלת

The rolling year net income per share dynamics for Imunon, Inc. (IMNN) reflect the impact of logistical risks and patent disputes with Asia. Now 67.60 becomes the new value for this metric. Flexibility is maintained through the outsourcing of production and testing to external partners. Growth prospects are based on the development of innovative DNA-based drugs to combat infections and oncology.
פילוחי מדדים פיננסיים ומדדי שוק עבור Imunon Inc (IMNN)

For Imunon, Inc. (IMNN), whose market capitalization depends on the success of clinical trials within the cancer immunotherapy niche, this metric serves as an indicator of actual business efficiency. By analyzing the year-over-year (YoY) percentage growth of earnings per share over 12 months on the GURU.Markets platform, an investor assesses the annual net income trend, which allows them to filter out short-term volatility and avoid overpaying for the asset.